We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid Zika Detection Test Uses Smartphone Technology

By LabMedica International staff writers
Posted on 10 Jul 2018
The Zika virus, which continues to cause microcephaly and other neurological complications in infants whose mothers were infected during pregnancy, remains a public health concern.

Traditional virus diagnostics rely on detecting antibodies in a person's bloodstream that target Zika. More...
However, many closely related viruses, including dengue, can elicit similar antibodies, leading to a high false positive rate for such tests.

Investigators from Brigham and Women's Hospital (Boston, MA; USA) and their colleagues have developed a new way to rapidly and accurately diagnose Zika using mobile health technologies that could potentially be deployed in resource-limited settings. The team used nanotechnology and developed tiny platinum nanomotors that target Zika as well as microbeads that bind the virus. When both components are added to a sample containing Zika, they form a three-dimensional complex that moves in the presence of hydrogen peroxide (H2O2). This movement can be detected using a smartphone hooked up to an optical device that costs USD 5.

The presence of virus in a testing sample results in the accumulation of platinum (Pt)-nanomotors on the surface of beads, causing their motion in H2O2 solution. Then the virus concentration is detected in correlation with the change in beads motion. The developed nanomotor-based bead-motion cell phone (NBC) system was capable of detecting Zika virus (ZIKV) in samples with virus concentrations as low as 1 particle/μL. The NBC system allowed a highly specific detection of ZIKV in the presence of the closely related dengue virus and other neurotropic viruses, such as herpes simplex virus type 1 and human cytomegalovirus.

Mohamed Shehata Draz, PhD, a postdoctoral fellow and the first author of the study, said, “The NBC system has the potential to be used at the point of care for disease detection in both developed and developing countries. This is an important way to eliminate the social stress related to Zika virus infection and health problems specifically related to newborns.” The study was published online on May 16, 2018, in the journal ACS Nano.

Related Links:
Brigham and Women's Hospital

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.